Alimera Sciences — Q3 2017 Earnings Presentation
16 slides from Alimera Sciences's earnings presentation, Nov 2, 2017
Slide 1: Third Quarter 2017 Results Conference Call
Third Quarter 2017 Results Conference Call Thursday, November 2, 2017 Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the opportunity for further growth in 2017 for ILUVIEN and the potential approval and commercialization of ILUVIEN
Slide 3: Third Quarter 2017 Highlights
$8.3 M $9.8 M 3Q16 3Q17 3 Third Quarter 2017 Highlights Revenue Growth • 18% revenue growth compared to the third quarter of 2016. • Partnership announced in France; first units sold in Italy. • Rights to posterior uveitis secured for ILUVIEN in the EU, Middle East & Africa. 18% © 2017 Alimera Scien
Slide 4: USER Study Overview
USER Study Overview 4 © 2017 Alimera Sciences, Inc., All Rights Reserved Center Patients Treated, n (%) Eyes Treated, n All Centers 130 (100%) 160 Cincinnati Eye 37 (28.5%) 49 Georgia Retina 15 (11.5%) 19 Retina Health Institute 53 (40.8%) 59 Southern Eye 25 (19.2%) 33 Patients must have received IL
Slide 5: Change in Visual Acuity, Entire Population
Change in Visual Acuity, Entire Population 5 © 2017 Alimera Sciences, Inc., All Rights Reserved
Slide 6: Minimal IOP Increase
6 © 2017 Alimera Sciences, Inc., All Rights Reserved Minimal IOP Increase
Slide 7: IOP Related Events - DME
7 © 2017 Alimera Sciences, Inc., All Rights Reserved IOP Related Events - DME (N eyes = 160) IOP-Related Event Before ILUVIEN Administration After ILUVIEN Administration P-Value N % N % IOP Elevation to over 21 mmHg 61 38.1% 49 30.6% 0.195 IOP Elevation to over 25 mmHg 24 15.0% 24 15.0% 1.000 IOP El
Slide 8: Fluocinolone Acetonide for Non-Infectious Uveitis Affecting The Posterior Segment
8 © 2017 Alimera Sciences, Inc., All Rights Reserved Expect approval during 2018 and expect to begin marketing ILUVIEN for Posterior Uveitis in 2019 Fluocinolone Acetonide for Non-Infectious Uveitis Affecting The Posterior Segment (NIU-PS) Primary End Point at 6 Months – Reduction in the Recurrence
Slide 9: IOP Related Events – Posterior Uveitis
IOP-Related Event FAc Insert (N=188) Sham Injection (N=94) N % N % IOP Elevation to over 25 mmHg 36 19.1% 7 (7.4%) IOP Elevation to over 30 mmHg 22 11.7% 3 3.2% IOP-lowering medication 42 22.3% 14 14.9% IOP-lowering Surgery 3 1.6% 2 2.1% Cataract Surgery (N/Phakic) 17/103 16.5% 4/56 7.1% 9 Expect ap
Slide 10: Uveitis Indication for ILUVIEN
10 Uveitis Indication for ILUVIEN © 2017 Alimera Sciences, Inc., All Rights Reserved • Announced acquisition of rights for Posterior Uveitis for ILUVIEN in Europe, the Middle East and Africa • Filing for label variation with the MHRA in the 17 EU countries where ILUVIEN is approved in the first quar
Slide 11: Financial Overview
Financial Overview Rick Eiswirth, President & CFO
Slide 12: 3Q17 Financial Overview: Revenue
$8.3M $2.1M $6.2M $9.8M $2.6M $7.1M Global Revenue International Revenue U.S. Revenue 12 3Q17 Financial Overview +18% +24% +15% © 2017 Alimera Sciences, Inc., All Rights Reserved 3Q17 3Q16
Slide 13: 3Q17 Financial Overview: Expenses and Adjusted EBITDA
$15.1M $7.2M $16.9M $12.6M $3.8M $14.6M Operating Expenses GAAP Operating Loss Adjusted Operating Expenses* 13 © 2017 Alimera Sciences, Inc., All Rights Reserved *Please see Non-GAAP financial information on slide 15 of this presentation ($5.4 M) ($1.8 M) Adjusted EBITDA* (17%) (47%) (14%) 3Q17 Fina
Slide 14: Closing Remarks
14 Closing Remarks © 2017 Alimera Sciences, Inc., All Rights Reserved • Continue to focus on profitable revenue growth. • USER Study data expected to drive further acceptance of ILUVIEN in the U.S. • Continue to build product pipeline for ILUVIEN with first approvals of posterior uveitis expected du
Slide 15: Non-GAAP Financial Information
15 Non-GAAP Financial Information © 2017 Alimera Sciences, Inc., All Rights Reserved Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GAAP figures. This
Slide 16: Third Quarter 2017 Results Conference Call
Third Quarter 2017 Results Conference Call Thursday, November 2, 2017